Dr. Neil Tolson Head, In Commerce Substances Unit 1 New Substances Assessment and Control Bureau - PowerPoint PPT Presentation

1 / 17
About This Presentation
Title:

Dr. Neil Tolson Head, In Commerce Substances Unit 1 New Substances Assessment and Control Bureau

Description:

Title: Andrew Beck, Head Environmental Assessment Unit (EAU) New Substances Assessment and Control Bureau Chemicals Management Directorate Health Canada – PowerPoint PPT presentation

Number of Views:539
Avg rating:3.0/5.0
Slides: 18
Provided by: ABE103
Category:

less

Transcript and Presenter's Notes

Title: Dr. Neil Tolson Head, In Commerce Substances Unit 1 New Substances Assessment and Control Bureau


1
Dr. Neil TolsonHead, In Commerce Substances
Unit 1New Substances Assessment and Control
Bureau
  • The In Commerce List
  • EnviroPharm 2009
  • O1 October 2009

2
Introduction
  • Background
  • Revision Process
  • Communications Strategy for Revision Process
  • Next Steps
  • Contact Information and Website Address

3
Background What is the In Commerce List
  • The In Commerce List (ICL) consists of
    approximately 9,000 substances in products
    subject to the regulations of the Food and Drugs
    Act that were in commerce between 01 Jan. 1987
    and 13 Sept. 2001.
  • The current list was created in 2001 from records
    in HC commodity groups.
  • Each entry has a maximum of three pieces of
    information CAS Name, CAS Number and alternate
    name.
  • Substances on the ICL are defined as new
    substances under CEPA, i.e., they are not on the
    DSL, however, under the current policy NSNR
    requests will not be made for ICL substances

4
Background The Need to Revise the ICL
  • The current list has a number of deficiencies,
    including
  • incorrect information, e.g., CAS numbers do not
    match CAS names
  • omissions substances in commerce that were not
    in HC records duplications the same substance
    may be present under a different name
  • substances on the DSL
  • lack of information most substances do not have
    a CAS Number and CAS Name the list does not
    contain structures, use patterns, or annual
    volumes

5
Background Management of ICL Substances
  • Revision of the current ICL
  • 2. Categorization/prioritization substances on
    the revised ICL
  • 3. Assessment of risks of ICL substances to
    humans (indirect exposure) and to the environment
  • 4. Proposal of risk mitigation measures, where
    required

6
Revision Process Multi-stakeholder Consultations
  • The ICL technical subcommittee was established in
    2007 under the multi-stakeholder Environmental
    Assessment Working Group (EAWG).
  • The ICL subcommittees work has focused on what
    substances should be nominated to the revised
    ICL, what substances should be excluded, and the
    process on how to submit nominations to a revised
    ICL.

7
Revision Process Nomination Process
  • The revision of the ICL will be based on a
    two-phase nomination process
  • Industry will submit information to HC to enable
    the identification of each substance
  • For substances on the current ICL, no proof of in
    commerce required. Substances not on the current
    ICL will require proof of in commerce

8
Revision Process Additions to the Current ICL
  • Health Canada is accepting requests for
    additions to the ICL until the nomination process
    for revision of the ICL is initiated.
  • To date approximately 300 substances have been
    added to the ICL following receipt requests and
    assessment of the supporting information from
    manufactures and importers.
  • Enquiries on the process for submitting a
    request for additions to the ICL should be
    addressed to the In Commerce Substances Unit 1
    (see slide on contact information).

9
Revision Process Verification of Substance
Identity To Date
  • The identity of 2200 substances on the current
    ICL, approximately 25 of the List, has been
    verified through a contract with Chemical
    Abstract Services (CAS). These substances will be
    added directly to the revised ICL.

10
Communications Strategy Components
  • A communications strategy for stakeholders and
    the public has been prepared. The strategy
    includes distribution of the Guidance Document
    presentations to industry HC website for the
    ICL and, an e-mail address and telephone line
    for enquiries

11
Communications StrategyGuidance Document For
Nomination Process
  • A comprehensive Guidance Document on the
    nomination process will be available on line. It
    will contain information on what to nominate, how
    to nominate and nomination forms.

12
Communications Strategy HC Website
  • An updated ICL website has been activated,
    effective June 2009. A subscribers option is
    being be added for stakeholders and the
    subscribers will be notified automatically by
    e-mail of updates to the website.

13
Next Steps Nomination Process
  • Conclude consultations
  • Initiate the communications strategy, including
    production of the Guidance Document
  • Launch the first phase of the nomination process

14
Next Steps Prioritization Process
  • Preliminary work is being conducted by Health
    Canada on approaches to prioritize substances on
    the ICL.

15
Contact Information
  • Neil Tolson
  • Head, In Commerce Substances Unit 1
  • New Substances Assessment and Control Bureau
  • 123 Slater Street, 5th Floor
  • Ottawa Ontario K1A 0K9
  • PL 3505A
  • neil_ tolson _at_hc-sc-gc.ca
  • Tel. 613-941-0144

16
Website Address
  • Information on the ICL, including substances on
    the current list, can be obtained from the
    following website
  • http//www.hc-sc.gc.ca/ewh-emt/contaminants/perso
    n/impact/list/index-eng.php

17
Questions?
Write a Comment
User Comments (0)
About PowerShow.com